Delivering Comprehensive Solutions
CollabRx develops products that inform treatment planning by changing the way medical and scientific information is organized, interpreted and disseminated with the goal of providing high value knowledge in an easily accessible form.
CollabRx has developed Web-based resources and apps to provide expert-vetted interpretation of molecular cancer panels, including clinical next-generation sequencing of tumors, in collaboration with our Pan Cancer Molecular Oncology Editorial Board.
Genetic Variant Annotation™ (GVA™) Service
The CollabRx GVA Service provides for a fully automated and scalable medical informatics solution to inform patient treatment planning by seamlessly pairing the results of genetic sequencing tests (generated on any platform) with clinically actionable and dynamically updated knowledge (provided by CollabRx in the form of interpretive reports and datasets). Knowledge contained within GVA reports includes the clinical impact of specific genetic profiles and associated therapeutic strategies such as drugs and clinical trials. This content leverages the CollabRx semantic integration platform, a proprietary technology that enables CollabRx scientists and physicians to dynamically update the company’s knowledge base with the latest medical and scientific data available in the public domain. This knowledge is further contextualized in collaboration with CollabRx’s large network of leading clinical practitioners in the U.S. and Europe.
GVA – Comprehensive Content To Inform Therapeutic Decisions in Precision Oncology
The GVA Service supports interpretation of somatic mutation test results for adult solid tumors and hematological malignancies. The GVA interprets a wide variety of genetic alterations including single base pair substitutions, nucleotide insertions and deletions, frameshifts, copy number alterations/variants (CNVs) and genetic translocations/fusions. There are hundreds of therapeutically relevant biomarkers and thousands of genetic alterations, drugs, and annotated clinical trials in the GVA knowledge base. Summaries of evidence provided in GVA datasets support clinical decision-making and include expert-vetted commentary describing clinical impact, therapeutic strategies, and relevant drugs and clinical trials to consider during cancer treatment planning, including on and off-label therapeutic options. Clinical guidelines, citations from the peer-reviewed medical and scientific literature, and other authoritative sources of information are used to support of all information provided in GVA datasets.
More detailed information available on request.
CollabRx clinical products are point-of-care electronic resources to assist oncologists, other physicians and health care professionals, and cancer patients in creating a personalized treatment plan by leveraging the unique genetic profiles of a given patient’s tumor.
Therapy Finder® Applications
Therapy Finders are a series of Web-based expert system applications (“apps”) that enable physicians and their patients to learn which tests should be considered for tumor molecular analysis and how to use the results of those tests in evaluating therapy options including approved and investigational drugs and clinical trials. The rationale for knowledge delivered via CollabRx Therapy Finders is transparent, associated with peer-reviewed publications, and generated by CollabRx scientific staff in collaboration with editorial boards of leading clinical practitioners. Launch the Therapy Finder based on the type of cancer:
Therapy Finder apps are freely accessible, provided for specific cancer types, and delivered in a form optimized for health care professionals (Professional version) and patients and caregivers (Patient version). The Therapy Finder – Professional version is currently available for melanoma, colorectal, lung, and metastatic breast cancer. Other cancer types and Patient versions are in development. CollabRx also developed an oncology-specific mobile app, CancerRx, which incorporates key aspects of the web-based Therapy Finders and ultimately serves as a comprehensive point of care resource for physicians and patients to obtain highly credible, expert-vetted and dynamically updated information to guide cancer treatment planning. Read the press release.